Clinical Trial Update: FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of FR901228 in patients with refractory or progressive small cell lung cancer or non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer
• Stage Iiia Non-small Cell Lung Cancer
• Stage Iiib Non-small Cell Lung Cancer

Drugs mentioned

• FR901228 (romidepsin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED